header

Xenograft Tumour Models

Cell Line Cancer Type Cell Implantation Site
A431 Epidermoid carcinoma s.c.
A549 Lung carcinoma (NSCLC) i.t.
Capan-1 Pancreatic s.c.
C-33A Cervical carcinoma s.c.
DOHH-2 B-cell carcinoma s.c.
DU145 Prostate carcinoma s.c.
ES-2 Ovarian carcinoma s.c.or i.p.
H460 Large cell lung cancer s.c.or i.t.
HT-29 Colorectal carcinoma s.c.
H2126 Lung adenocarcinoma s.c.
HCT-116 Colorectal carcinoma s.c.
HL-60 Promyeloblast s.c.
JIMT-1 Breast cancer, Herceptin resistant s.c.
JVM-2 B-cell leukemia s.c.
K562 Chronic myelogenous leukemia s.c.
LS180 Colorectal adenocarcinoma s.c.
LS174T Colon carcinoma i.s.
MCF-7 & MCF-7 HER-2 Breast adenocarcinoma s.c.
MDA-MB-231 Breast adenocarcinoma s.c.
MDS-MB-435 Breast carcinoma s.c.
MDA-MB-435 HER-2 Breast carcinoma s.c.
MDA435/LCC6 Breast carcinoma s.c./i.c..o.t.
MeWo Melanoma s.c.
MiaPaCa-2 Pancreatic s.c.
NCI/ADR-RES Ovarian, resistant s.c.
OVCAR-3 Ovarian s.c.or i.p.
PANC-1 Pancreas s.c.
PC-3 Prostate adenocarcinoma s.c.
SKOV-3 Ovarian adenocarcinoma s.c.or i.p.
SF188 Glioblastoma, PTEN (+) s.c.
U87MG Glioblastoma, PTEN (-) s.c.
U87GR PTEN catalytically inactive s.c.
U87.23 PTEN inducible PTEN inducible s.c.
Z138 Mantle cell lymphoma s.c./i.v.

s.c.: subcutaneous; i.t.: intrathoracic; i.p.: intraperitoneal, i.c.: intracardiac; i.v.: intravenous; o.t.: orthotopic


Please contact the Pharmacology Core (pharma@bcprc.ca) for more information.

 Pharmacology Service Request Form